Jump to content
Wikipedia The Free Encyclopedia

Methoxyetomidate

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Methoxyetomidate
Clinical data
Other namesET-26
Identifiers
  • 2-methoxyethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate
CAS Number
PubChem CID
Chemical and physical data
Formula C15H18N2O3
Molar mass 274.320 g·mol−1
3D model (JSmol)
  • [C@H](C)(N1C(C(OCCOC)=O)=CN=C1)C2=CC=CC=C2
  • InChI=InChI=1S/C15H18N2O3/c1-12(13-6-4-3-5-7-13)17-11-16-10-14(17)15(18)20-9-8-19-2/h3-7,10-12H,8-9H2,1-2H3/t12-/m1/s1
  • Key:JJSJTELMIQBHDE-GFCCVEGCSA-N

Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1] [2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[3] [1]

References

[edit ]
Inhalational
Injection
Phenols
Barbiturates
Benzodiazepines
Opioids
Arylcyclohexylamines
Neuroactive steroids
Others
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

AltStyle によって変換されたページ (->オリジナル) /